{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:37:46Z","timestamp":1777581466138,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,6,21]],"date-time":"2020-06-21T00:00:00Z","timestamp":1592697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This article reviews clinical trials to assess the efficacy, safety, and clinical application of trifarotene 0.005% cream (Aklief).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A systematic review of the literature was performed using the terms trifarotene OR Aklief OR CD5789 in MEDLINE (PubMed) and EMBASE databases. Articles prior to May 2020 were considered for inclusion. Bibliographies and ClinicalTrials.gov were also searched to identify further studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Relevant English language and human studies related to pharmacology, clinical trials, and safety were considered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>In the 52-week phase III trial, treatment success rates for facial acne (Investigator Global Assessment [IGA] rating of no or almost no acne) and truncal acne (Physician\u2019s Global Assessment [PGA] rating of no or almost no acne) were 65.1% and 66.9%, respectively. Overall success rates (IGA and PGA success in the same patient) were 57.9%; 52.8% of patients had a Dermatology Quality of Life Index score of 0 or 1, compared with 22.6% at baseline. Trifarotene was well tolerated, with pruritus, irritation, and sunburn as the most common adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Trifarotene is a newly Food and Drug Administration\u2013labeled fourth-generation topical retinoid that shows particular promise in the treatment of facial and truncal acne vulgaris. It is an effective and safe addition to currently available retinoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Trifarotene is effective and safe for treatment of facial and truncal acne. Future trials should compare its efficacy and tolerability with that of the older, clinically established retinoids. Despite efficacy, cost may be a prohibitive factor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1060028020934892","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T02:06:38Z","timestamp":1592791598000},"page":"111-116","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Trifarotene for the Treatment of Facial and Truncal Acne"],"prefix":"10.1177","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1290-1415","authenticated-orcid":false,"given":"Katheryn A.","family":"Bell","sequence":"first","affiliation":[{"name":"Georgetown University School of Medicine, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin M.","family":"Brumfiel","sequence":"additional","affiliation":[{"name":"Georgetown University School of Medicine, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-4217","authenticated-orcid":false,"given":"Wasim","family":"Haidari","sequence":"additional","affiliation":[{"name":"Georgetown University School of Medicine, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Boger","sequence":"additional","affiliation":[{"name":"MedStar Washington Hospital Center and MedStar Georgetown University Hospital, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,6,21]]},"reference":[{"key":"bibr1-1060028020934892","first-page":"s51","volume":"17","author":"Chien A","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"bibr2-1060028020934892","unstructured":"Retin-A Micro (tretinoin). Prescribing information. Accessed May 17, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020475s021lbl.pdf"},{"key":"bibr3-1060028020934892","unstructured":"Tazorac (tazarotene). Prescribing information. Accessed May 17, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/021184s007lbl.pdf"},{"key":"bibr4-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-019-00423-z"},{"key":"bibr5-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.1390s2003.x"},{"key":"bibr6-1060028020934892","unstructured":"Stiefel. Soriatane (acitretin) capsules. Accessed May 18, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/019821s023lbl.pdf"},{"key":"bibr7-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00112.x"},{"key":"bibr8-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.04.036"},{"key":"bibr9-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.10.9.8801176"},{"key":"bibr10-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16719"},{"key":"bibr11-1060028020934892","unstructured":"Center for Drug Evaluation and Research. Trifarotene NDA multidisciplinary review and evaluation. Accessed April 25, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211527Orig1s000MultidisclipineR.pdf"},{"key":"bibr12-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.044"},{"key":"bibr13-1060028020934892","unstructured":"Double-blind, placebo-controlled study to evaluate 3 doses of a novel tetracycline in the treatment of facial acne vulgaris. ClinicalTrials.gov identifier: NCT01628549. Published June 26, 2012. Accessed April 3, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01628549"},{"key":"bibr14-1060028020934892","unstructured":"Double-blind efficacy and safety of CD5789 (trifarotene) 50\u00b5g\/g cream versus vehicle cream in acne vulgaris. ClinicalTrials.gov identifier: NCT02556788. Accessed April 3, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02556788?term=NCT02556788&draw=2&rank=1"},{"key":"bibr15-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15794"},{"key":"bibr16-1060028020934892","unstructured":"CD5789 (trifarotene) long term safety study on acne vulgaris. ClinicalTrials.gov identifier: NCT02189629. Accessed April 3, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02189629?term=NCT02189629&draw=2&rank=1"},{"key":"bibr17-1060028020934892","first-page":"1783","volume":"7","author":"Nagpal S","year":"1996","journal-title":"Cell Growth Differ"},{"key":"bibr18-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12469889"},{"key":"bibr19-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1016\/0012-1606(91)90434-5"},{"key":"bibr20-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(97)70059-8"},{"key":"bibr21-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.12.037"},{"key":"bibr22-1060028020934892","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11100490"},{"key":"bibr23-1060028020934892","unstructured":"GoodRx. Aklief prices, coupons & savings tips. Accessed April 3, 2020. https:\/\/www.goodrx.com\/aklief"},{"key":"bibr24-1060028020934892","unstructured":"Galderma CareConnect. Patient savings card info for patients. Accessed May 17, 2020. https:\/\/www.galdermacc.com\/patients"},{"key":"bibr25-1060028020934892","unstructured":"GoodRx. Retinoids. Accessed April 14, 2020. https:\/\/www.goodrx.com\/retinoids"},{"key":"bibr26-1060028020934892","doi-asserted-by":"publisher","DOI":"10.1590\/s0365-05962012000600007"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020934892","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020934892","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020934892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:38Z","timestamp":1777374938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020934892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/1060028020934892"],"URL":"https:\/\/doi.org\/10.1177\/1060028020934892","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,21]]}}}